You just read:

Asterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR Phase 1/2a Clinical Trial in Complete Cervical Spinal Cord Injury

News provided by

Asterias Biotherapeutics, Inc.

Jul 12, 2016, 06:30 ET